US Reclassifies Weed: Can Cannabis ETFs Give Your Portfolio a New High?
Medical marijuana's US reclassification revives cannabis ETFs like WEED, with tax relief and reform hopes fueling sharp gains across the sector.
More News
4 Best-Performing ETF Areas of Last Week
Cannabis, semis, crude & hydrogen ETFs led last week as AI momentum, policy boost and Middle East tensions shaped market trends.
Tilray Stock Eyes Breakout Week: Trump’s Cannabis Order Opens Door To US Cancer Market Entry
Trump has also called on Congress to preserve access to full-spectrum CBD products and expand research.
TLRY, CGC, ACB, MSOS Pare Early Gains After Marijuana Reclassification: Retail Says ‘Weed Industry Is Reborn’
The U.S. Department of Justice formally moved to reclassify state-licensed medical marijuana as a less dangerous drug, four months after President Donald Trump signed an executive order.
AdvisorShares Issues Statement on Finalization of Federal Cannabis Rescheduling
AdvisorShares Issues Statement on Finalization of Federal Cannabis Rescheduling AdvisorShares Issues Statement on Finalization of Federal Cannabis Rescheduling PR Newswire BETHESDA, Md., April 23...
TLRY, CGC, IGC Stocks Light Up On Trump Pot Reclassification Hopes This Week
Axios reported on Wednesday, citing an administration official, that the Trump administration is slated to reclassify marijuana as soon as Wednesday.
Top & Flop ETF Areas of 2025 (Revised)
Silver, gold & platinum ETFs (SLVP, SILJ, GOEX) crushed it in 2025, while MEME & VIXY lagged.
Santa Rally Falls Short: Top ETF Performers of December
Santa Rally fizzled as markets stumbled, but ETFs tied to cannabis (MSOS, WEED), metals (SLV, PPLT) and space (UFO) surged.
Top & Flop ETF Areas of 2025
Silver, gold & platinum ETFs (SLVP, SILJ, GOEX) crushed it in 2025, while MSOS, MEME & VIXY lagged amid policy, hype & calm markets.
Tilray, Aurora Cannabis, Trulieve Pull Back After Trump Marijuana Order Rally Runs Out Of Steam
Trump clarified that the order is not federal legalization and does not allow for recreational use nationwide, but is instead aimed at improving medical marijuana and cannabidiol research.